Association between iridocyclitis and immune-related disease: A 2-sample Mendelian randomization study

Yao Yao,Qian Wang,Wenbin Wei
DOI: https://doi.org/10.1097/md.0000000000040663
IF: 1.6
2024-12-01
Medicine
Abstract:Iridocyclitis, also referred to as anterior uveitis, is an inflammatory condition targeting the anterior segment of the uveal tract, specifically the iris and ciliary body. It stands as the most prevalent form of iridocyclitis and represents a significant cause of ocular morbidity worldwide, with global incidence rates of anterior uveitis ranging from 12 to 52 cases per 100,000 individuals annually. [ 1–3 ] Iridocyclitis may occur as an isolated ocular event or in association with systemic diseases, particularly those involving immune dysregulation. Central to its pathogenesis are pro-inflammatory cytokines, including interleukins (IL-1, IL-6, IL-17), tumor necrosis factor-alpha (TNF-α), and interferon-gamma, which orchestrate immune cell activation and tissue infiltration. [ 4 , 5 ] These cytokines initiate a cascade of events involving chemokines such as CCL2 and CXCL8, facilitating the recruitment of leukocytes and perpetuating local inflammation within the uveal tissue. Immune cells play pivotal roles in iridocyclitis, with effector T lymphocytes, particularly Th1 and Th17 subsets, significantly contributing to disease severity. [ 6 , 7 ] Th1 cells produce IFN-γ, driving macrophage activation and tissue damage, while Th17 cells release IL-17, perpetuating chronic inflammation and tissue remodeling. [ 8 , 9 ] Activated macrophages further exacerbate inflammation through the secretion of pro-inflammatory cytokines and reactive oxygen species, contributing to oxidative stress and subsequent damage to retinal and choroidal tissues.
medicine, general & internal
What problem does this paper attempt to address?